|
業務類別
|
-- |
|
業務概覽
|
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World. |
| 公司地址
| Virdings alle 22, Uppsala, SWE, 75105 |
| 電話號碼
| +46 187808800 |
| 傳真號碼
| +46 187808888 |
| 公司網頁
| https://www.orexo.com |
| 員工數量
| 74 |
| Mr. Fredrik Jarrsten |
Executive Vice President and Chief Financial Officer |
-- |
02/04/2025 |
| Mr. Nikolaj Sorensen |
Chief Executive Officer and President |
-- |
02/04/2025 |
|
|
| Mr. James Julian Noble, M.A. |
Chairman of the Board |
02/04/2025 |
| Ms. Christine Rankin |
Independent Director |
02/04/2025 |
| Mr. Robin Evers |
Director |
02/04/2025 |
| Mr. G. Frederick Wilkinson |
Independent Director |
02/04/2025 |
| Mr. Staffan Lindstrand |
Independent Director |
02/04/2025 |
| Dr. Friedrich von Bohlen und Halbach, PhD |
Independent Director |
02/04/2025 |
|
|
|
|
